237 related articles for article (PubMed ID: 2769847)
1. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
Sarosdy MF; Lamm DL
J Urol; 1989 Sep; 142(3):719-22. PubMed ID: 2769847
[TBL] [Abstract][Full Text] [Related]
2. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
[TBL] [Abstract][Full Text] [Related]
3. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
4. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
Lamm DL
J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
[TBL] [Abstract][Full Text] [Related]
5. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
6. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
[TBL] [Abstract][Full Text] [Related]
7. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer immunotherapy.
Lamm DL; Thor DE; Stogdill VD; Radwin HM
J Urol; 1982 Nov; 128(5):931-5. PubMed ID: 6757467
[TBL] [Abstract][Full Text] [Related]
9. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.
deKernion JB; Huang MY; Lindner A; Smith RB; Kaufman JJ
J Urol; 1985 Apr; 133(4):598-601. PubMed ID: 3981707
[TBL] [Abstract][Full Text] [Related]
10. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
Brosman SA
J Urol; 1982 Jul; 128(1):27-30. PubMed ID: 6809960
[TBL] [Abstract][Full Text] [Related]
11. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
12. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
[TBL] [Abstract][Full Text] [Related]
13. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial.
Hudson MA; Ratliff TL; Gillen DP; Haaff EO; Dresner SM; Catalona WJ
J Urol; 1987 Aug; 138(2):295-8. PubMed ID: 3298694
[TBL] [Abstract][Full Text] [Related]
14. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin.
Bretton PR; Herr HW; Kimmel M; Whitmore WF; Laudone V; Oettgen HF; Fair WR
J Urol; 1990 Apr; 143(4):710-2; discussion 712-3. PubMed ID: 2313796
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer.
Torrence RJ; Kavoussi LR; Catalona WJ; Ratliff TL
J Urol; 1988 May; 139(5):941-4. PubMed ID: 3361668
[TBL] [Abstract][Full Text] [Related]
17. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
18. Intravesical bacillus Calmette-Guerin in the treatment of superficial transitional cell carcinoma of the bladder.
Pansadoro V; De Paula F
J Urol; 1987 Aug; 138(2):299-301. PubMed ID: 3599242
[TBL] [Abstract][Full Text] [Related]
19. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.
Bretton PR; Herr HW; Whitmore WF; Badalament RA; Kimmel M; Provet J; Oettgen HF; Melamed MR; Fair WR
J Urol; 1989 Apr; 141(4):853-6. PubMed ID: 2926879
[TBL] [Abstract][Full Text] [Related]
20. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
Catalona WJ; Hudson MA; Gillen DP; Andriole GL; Ratliff TL
J Urol; 1987 Feb; 137(2):220-4. PubMed ID: 3806806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]